Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line - Immunotherapy

No Prior Therapy With PD-1/PD-L1
- THOR0006
  Phase III of Nivolumab with Vorolanib in Refractory Thoracic Tumors
  PI: Wakelee NCTN

On anti PD-1/ anti PD-L1 with response, stable disease or modest progression
- LUN0085
  Phase II Pembrolizumab in Metastatic Non-Squamous NSCLC Examining Circulating Tumor DNA Levels
  PI: Neal Stanford

- LUN0088
  Phase II Radical-Dose RT with Anti-PD-1/ Anti-PD-L1 Immunotherapy in Non-Small Cell Lung Cancer
  PI: Gensheimer Stanford

- THOR0006
  Phase III of Nivolumab with Vorolanib in Refractory Thoracic Tumors
  PI: Wakelee NCTN

Failed Therapy PD-L1
- LUN017
  Phase II/III of Atezolizumab +/- Cabozantinib vs Docetaxel in Metastatic Non-Small Cell Lung Cancer
  PI: Neal Pending

- LUN0107
  Phase Ib/II Grapiprant +/- Pembrolizumab vs Avytisel in Advanced or Metastatic Post-PD-1/L NSCLC Adenocarcinoma
  PI: Wakelee Aris Therapeutics

Lung Map Screening Study
- ECOG-ACRIN-S1880A
  Phase II Ramucirumab + MK3475 vs SoC in Previously Tx w/ Immunotherapy for Stage IV/Recurrent NSCLC
  PI: Neal

- ECOG-ACRIN-S1900C
  Phase II Talazoparib + Avelumab in Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer
  PI: Neal ECOG-ACRIN

KEY
- Pending
- Open for Enrollment
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold